- Home
- EDIT vs CRAC Comparison
EDIT vs CRAC Comparison
Compare EDIT & CRAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDIT | CRAC |
|---|---|---|
| Founded | 2013 | 2025 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.0M | 216.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | EDIT | CRAC |
|---|---|---|
| Price | $2.86 | $10.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.92 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 154.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.29 | $9.90 |
| 52 Week High | $4.54 | $10.07 |
Technical Indicators
Market Signals| Indicator | EDIT | CRAC |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 66.83 |
| Support Level | $1.95 | $9.97 |
| Resistance Level | $3.17 | N/A |
| Average True Range (ATR) | 0.26 | 0.01 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 17.95 | 88.89 |
Price Performance
Historical ComparisonAbout EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About CRAC Crown Reserve Acquisition Corp. I Class A Ordinary Shares
Crown Reserve Acquisition Corp I is a blank check company.